137 related articles for article (PubMed ID: 23582150)
21. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis.
Fedele L; Bianchi S; Zanconato G; Portuese A; Raffaelli R
Fertil Steril; 2001 Mar; 75(3):485-8. PubMed ID: 11239528
[TBL] [Abstract][Full Text] [Related]
22. Menstrual suppression for adolescents.
Altshuler AL; Hillard PJ
Curr Opin Obstet Gynecol; 2014 Oct; 26(5):323-31. PubMed ID: 25110977
[TBL] [Abstract][Full Text] [Related]
23. Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis.
Andres MP; Mendes RFP; Hernandes C; Araújo SEA; Podgaec S
Einstein (Sao Paulo); 2019 May; 17(2):eAO4583. PubMed ID: 31066795
[TBL] [Abstract][Full Text] [Related]
24. Controversies in the Management of Endometrioma: To Cure Sometimes, to Treat Often, to Comfort Always?
Johnstone EB; Link MH
Clin Obstet Gynecol; 2015 Dec; 58(4):754-64. PubMed ID: 26512440
[TBL] [Abstract][Full Text] [Related]
25. [The menstrual cycle after oral contraceptives].
Hauser GA; Girotti M
Geburtshilfe Frauenheilkd; 1967 Jun; 27(6):626-30. PubMed ID: 5592760
[No Abstract] [Full Text] [Related]
26. A pilot study on the off-label use of valproic acid to treat adenomyosis.
Liu X; Guo SW
Fertil Steril; 2008 Jan; 89(1):246-50. PubMed ID: 17239872
[TBL] [Abstract][Full Text] [Related]
27. The levonorgestrel-releasing intrauterine system is associated with a reduction in dysmenorrhoea and dyspareunia, a decrease in CA 125 levels, and an increase in quality of life in women with suspected endometriosis.
Yucel N; Baskent E; Karamustafaoglu Balci B; Goynumer G
Aust N Z J Obstet Gynaecol; 2018 Oct; 58(5):560-563. PubMed ID: 29359457
[TBL] [Abstract][Full Text] [Related]
28. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman.
Razzi S; Fava A; Sartini A; De Simone S; Cobellis L; Petraglia F
BJOG; 2004 Feb; 111(2):182-4. PubMed ID: 14723761
[No Abstract] [Full Text] [Related]
29. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas.
Adachi K; Takahashi K; Nakamura K; Otake A; Sasamoto N; Miyoshi Y; Shioji M; Yamamoto Y; Fujitani M; Wakimoto A; Tokuhira A; Kobayashi E; Yoshimura A; Sawada K; Kimura T
Gynecol Endocrinol; 2016 Aug; 32(8):646-649. PubMed ID: 26890948
[TBL] [Abstract][Full Text] [Related]
30. Effective post-laparoscopic treatment of endometriosis with dydrogesterone.
Trivedi P; Selvaraj K; Mahapatra PD; Srivastava S; Malik S
Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():73-6. PubMed ID: 17943543
[TBL] [Abstract][Full Text] [Related]
31. [Levonorgestrel-releasing intrauterine system for treatment of dysmenorrhea associated with adenomyosis].
Sheng J; Lu D; Zhang JP; Cui GF
Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):467-70. PubMed ID: 17083813
[TBL] [Abstract][Full Text] [Related]
32. Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma.
Taniguchi F; Enatsu A; Ota I; Toda T; Arata K; Harada T
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():116-20. PubMed ID: 26115056
[TBL] [Abstract][Full Text] [Related]
33. Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial.
Tanmahasamut P; Saejong R; Rattanachaiyanont M; Angsuwathana S; Techatraisak K; Sanga-Areekul N
Gynecol Endocrinol; 2017 Jul; 33(7):534-539. PubMed ID: 28266234
[TBL] [Abstract][Full Text] [Related]
34. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial.
Harada T; Momoeda M; Taketani Y; Hoshiai H; Terakawa N
Fertil Steril; 2008 Nov; 90(5):1583-8. PubMed ID: 18164001
[TBL] [Abstract][Full Text] [Related]
35. Combined treatment of endometriosis. GnRH agonists and laparoscopic surgery.
Hemmings R
J Reprod Med; 1998 Mar; 43(3 Suppl):316-20. PubMed ID: 9564667
[TBL] [Abstract][Full Text] [Related]
36. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.
Carvalho N; Margatho D; Cursino K; Benetti-Pinto CL; Bahamondes L
Fertil Steril; 2018 Nov; 110(6):1129-1136. PubMed ID: 30396557
[TBL] [Abstract][Full Text] [Related]
37. Presurgical management of dysmenorrhea and endometriosis in a patient with Mayer-Rokitansky-Kuster-Hauser syndrome.
Elliott JE; Abduljabar H; Morris M
Fertil Steril; 2011 Aug; 96(2):e86-9. PubMed ID: 21718988
[TBL] [Abstract][Full Text] [Related]
38. Management of pelvic pain from dysmenorrhea or endometriosis.
Nasir L; Bope ET
J Am Board Fam Pract; 2004; 17 Suppl():S43-7. PubMed ID: 15575029
[TBL] [Abstract][Full Text] [Related]
39. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months.
Margatho D; Carvalho NM; Bahamondes L
Eur J Contracept Reprod Health Care; 2020 Apr; 25(2):133-140. PubMed ID: 32069126
[No Abstract] [Full Text] [Related]
40. [Painful symptoms of pelvic endometriosis].
Zhou Y; Wu B
Zhonghua Fu Chan Ke Za Zhi; 1995 Jan; 30(1):30-3. PubMed ID: 7750405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
